PMID- 17373693
OWN - NLM
STAT- MEDLINE
DCOM- 20071107
LR  - 20200930
IS  - 1552-4841 (Print)
IS  - 1552-4841 (Linking)
VI  - 144B
IP  - 6
DP  - 2007 Sep 5
TI  - Response to lithium prophylaxis: interaction between serotonin transporter and 
      BDNF genes.
PG  - 820-3
AB  - Both serotonin transporter and brain-derived neurotrophic factor (BDNF) genes 
      have been previously implicated in the efficacy of lithium prophylaxis. The aim 
      of the present study was to assess a possible interaction between serotonin 
      transporter genotype (5HTTLPR) and BDNF Val66Met polymorphism, and the 
      prophylactic response to lithium. The study was performed on 111 patients with 
      bipolar mood disorders (43 male, 68 female), aged 30-77 (mean 54 years) who have 
      been treated with lithium carbonate for at least 5 years (5-27 years, mean 15 
      years). In the group studied, 31 patients (28%) were classified as excellent 
      responders (ER), 54 (49%) as partial responders (PR), and 26 (23%) as 
      non-responders (NR) to lithium prophylaxis. Age at onset of the illness, duration 
      of illness before treatment introduction and on lithium as well as number of 
      affective episodes before lithium treatment did not differ between these three 
      subgroups of patients. A significant interaction between BDNF and 5HTTLPR 
      polymorphism and lithium response was found. S individuals (patients with s/s or 
      s/l genotype) having Val/Val genotype were significantly more frequent in NR 
      compared with ER or/and PR. Also, S individuals showed extreme differences in 
      response to lithium prophylaxis depending on having either Val/Val or (Val/Met + 
      Met/Met) genotypes of BDNF polymorphism: 9/48 (19%) of ER and 18/48 (37%) of NR 
      in the first group, and 12/30 (40%) and 1/30 (3%) in the second group, 
      respectively. The results obtained may show a significant epistatic interaction 
      between 5-HTTLPR and BDNF polymorphism, and response to lithium prophylaxis.
CI  - Copyright 2007 Wiley-Liss, Inc.
FAU - Rybakowski, Janusz K
AU  - Rybakowski JK
AD  - Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, 
      Poland. rybakows@wlkp.top.pl
FAU - Suwalska, Aleksandra
AU  - Suwalska A
FAU - Skibinska, Maria
AU  - Skibinska M
FAU - Dmitrzak-Weglarz, Monika
AU  - Dmitrzak-Weglarz M
FAU - Leszczynska-Rodziewicz, Anna
AU  - Leszczynska-Rodziewicz A
FAU - Hauser, Joanna
AU  - Hauser J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Med Genet B Neuropsychiatr Genet
JT  - American journal of medical genetics. Part B, Neuropsychiatric genetics : the 
      official publication of the International Society of Psychiatric Genetics
JID - 101235742
RN  - 0 (Antimanic Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (SLC6A4 protein, human)
RN  - 0 (Serotonin Plasma Membrane Transport Proteins)
RN  - 2BMD2GNA4V (Lithium Carbonate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antimanic Agents/*therapeutic use
MH  - Bipolar Disorder/*drug therapy/*genetics/psychology
MH  - Brain-Derived Neurotrophic Factor/*genetics
MH  - Female
MH  - Genotype
MH  - Humans
MH  - Lithium Carbonate/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Polymorphism, Genetic
MH  - Serotonin Plasma Membrane Transport Proteins/*genetics
EDAT- 2007/03/22 09:00
MHDA- 2007/11/08 09:00
CRDT- 2007/03/22 09:00
PHST- 2007/03/22 09:00 [pubmed]
PHST- 2007/11/08 09:00 [medline]
PHST- 2007/03/22 09:00 [entrez]
AID - 10.1002/ajmg.b.30420 [doi]
PST - ppublish
SO  - Am J Med Genet B Neuropsychiatr Genet. 2007 Sep 5;144B(6):820-3. doi: 
      10.1002/ajmg.b.30420.